Immunogenicity validation of recombinant BCG expressing optimized E2 gene of bovine viral diarrhea disease virus

曾范利,张云,张梦,时坤,李建明,郝俊伟,孙凡婷,杜锐
DOI: https://doi.org/10.16656/j.issn.1673-4696.2014.02.012
2014-01-01
Abstract:To evaluate immune efficacy of recombinant BCG(rBCG),which encodes bovine viral diarrhea disease virus(BVDV)E2protein,groups of specific pathogen free(SPF)mice were intraperitoneally injected with the recombinant pMV361-E2-1,pMV361-E2-2,pMV361-E2-3,pMV361-E2-4,pMV361-E2-5 and pMV361-E2-6,respectively.pMV361,inactivated BVDV vaccine,BCG and sterile normal saline were set as the control groups.The BVDV specific antibody,levels of CD4+,CD8+,IL-12and number of T-lymphocyte proliferation response were detected and estimated.In result,six groups of rBCG developed not only specific antibodies against BVDV and BCG in mice,but also T lymphocyte proliferation response.Moreover,the levels of CD4+,CD8+and IL-12production against BVDV antigens in the rBCG groups were higher than these in the control groups,and the results showed that the pMV361-E2-1-rBCG was better than the other groups.In conclusion,rBCG with different fragments of E2gene have a positive inductive effect on the specific humoral and cellular immunity.This study laid the foundation for study on new type gene engineering vaccines against BVDV.
What problem does this paper attempt to address?